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Learning objectives
 ► How to estimate risk of pregnancy in women 
with congenital heart disease.
 ► What to discuss during prepregnancy 
counselling in women with congenital heart 
disease.
 ► Global overview of follow- up during pregnancy.
InTroduCTIon
Pregnancy is a major life event for almost every 
woman. However, for women with heart disease 
pregnancy is associated with additional risks and 
deserves special attention. The number of preg-
nancies in women with congenital heart disease 
has increased over the past decades and is expected 
to rise further in the coming years.1 Physiolog-
ical changes in the cardiovascular system during 
pregnancy may bear a risk for those with congen-
ital heart disease who are not able to sufficiently 
adapt.2 Subsequently, heart failure, arrhythmias and 
worsening of the cardiac condition may compli-
cate pregnancy and expose mother and child to an 
increased risk of morbidity and mortality. Congen-
ital heart disease is often already diagnosed and 
treated at the time women start thinking about 
pregnancy, and hence counselling and risk predic-
tion can be offered. In contrast to acquired heart 
disease, congenital heart disease bears a relatively 
low risk of complications during pregnancy. This 
is partly attributable to good counselling and close 
follow- up in specialised centres. Dedicated guide-
lines on pregnancy and heart disease have become 
available in the past decade, enabling the physi-
cian to provide standard and individualised care 
during pregnancy.3 A multidisciplinary ‘pregnancy 
heart team’ is required to support management of 
counselling, follow- up and delivery. This review 
addresses risk stratification and counselling in 
women with congenital heart disease contemplating 
pregnancy.
Cardiovascular physiology during pregnancy
Pregnancy is associated with various physiological 
adaptions of the cardiovascular system.4–6 Cardiac 
output needs to increase up to 50% during preg-
nancy, to enable the fetal circulation, and this 
increase starts already during the first trimester. 
There is a 30%–40% decrease in vascular resis-
tance. As part of the cardiac output, plasma volume 
expands in the first and second trimester, followed 
by an increase in heart rate of around 10%–20%. 
Delivery further pushes these changes to a tempo-
rary maximum. After delivery, large fluid shifts are 
responsible for a transient volume overload in the 
first days post partum.
As a consequence of these haemodynamic 
changes, echocardiographic studies show a clear 
increase in left ventricular end- diastolic dimensions, 
while the systolic measurements remain stable.7 
The subsequent increase in stroke volume leads to 
a rise of the ventricular outflow tract velocity, and 
it mimics a hyperkinetic state. The same probably 
holds for the right ventricle, although less evidence 
is available. Finally, the expansion of stroke volume 
and lower afterload influence absolute regurgita-
tion volumes. Regurgitant lesions will therefore 
hardly be worse during pregnancy.
Hormonal changes influence the integrity of the 
vessel wall. The structure of the aortic wall may 
have a subtle weaker composition, which is not of 
significant importance to healthy women, but may 
enhance the risk of aortic dissection in women with 
aortic disease. Furthermore, pregnancy is known 
for its hypercoagulable state, which is very relevant 
in those with a mechanical prosthetic heart valve or 
Fontan circulation.
Pharmacokinetic processes will change during 
pregnancy, due to the increased plasma volume and 
total body water, and through changes in absorp-
tion, glomerular filtration rate, hepatic metabolism 
and protein binding activity.8 Moreover, drugs may 
cross the placental border and reach the fetal circu-
lation. The European Medicines Agency (EMA) and 
US Food and Drug Administration (FDA) provide 
available evidence for medication during pregnancy, 
which is helpful when considering or revising drug 
therapy during pregnancy and breast feeding.
rIsk sTraTIfICaTIon
Several risk scores have been proposed to estimate 
the risk of maternal complications during and after 
pregnancy (figure 1). The modified WHO (mWHO) 
risk classification provides an important step in 
recognition of risks. The stratification is based on 
the underlying diagnoses and may also give direc-
tion as to who should be referred immediately, and 
who may be evaluated in non- tertiary centres. In 
addition, two clinical risk tools are available: the 
CARdiac disease in PREGnancy (CARPREG) and 
the Zwangerschap bij Aangeboren HARtAfwijking 
(ZAHARA) risk scores. In women with congenital 
heart disease, the WHO classification seems to 
perform best,9 but the addition of clinical character-
istics will further enable an individualised strategy.
Prepregnancy investigations include thorough 
history taking, physical examination, an ECG, 
echocardiogram and exercise test. Clues like dimin-
ished exercise tolerance, symptoms of heart failure 
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figure 1 Risk tools modified WHO (mWHO), CARdiac disease in PREGnancy (CARPREG), Zwangerschap bij Aangeboren HARtAfwijking (ZAHARA), 
Registry Of Pregnancy And Cardiac disease (ROPAC). OR’s and rates are derived from cohorts consisting of approx. 60% patients congenital heart 
disease (63% in CARPREG II and 58% in ROPAC). Numbers derived from: Silversides et al, JACC, 2018; Drenthen et al, Eur Heart J, 2010; van Hagen et 
al, Eur J Heart Fail. NYHA, New York Heart Association functional class. OR, Odds Ratio
or palpitations may increase pregnancy risk. Also, 
a family history of sudden death or dissection is 
important information to enable risk stratification. 
Complete physical examination is required to reveal 
(progression of) heart murmurs, gallop sound, 
elevated central venous pressure, rales, hepato-
splenomegaly and peripheral oedema. Normal 
pregnancy complaints may be difficult to distinguish 
from symptoms and signs of heart failure during 
pregnancy. An ECG provides prognostic informa-
tion if for instance new or known atrial fibrillation 
is found. Signs of heart failure or atrial fibrillation 
before pregnancy are associated with a significant 
accumulation of complication risk.10
Prepregnancy echocardiography should 
be performed in every woman, with detailed 
assessment of the cardiac lesion, dimensions, 
ventricular function and filling pressures. These 
baseline measurements allow for serial follow- up 
during pregnancy. Exercise capacity, measuring 
VO2 max, is an established criterion used in the 
general evaluation of congenital heart disease, and 
a sufficient oxygen uptake is associated with better 
outcome of pregnancy as well.11 In individual 
cases, current cardiac state may be further inves-
tigated using other diagnostic modalities such as 
Holter, cardiac CT or magnetic resonance (CMR) 
imaging. CT and CMR are used to determine 
aortic diameters in those with predisposition to or 
established aortic pathology. Women with aortic 
disease presenting during pregnancy, without 
preconception counselling, should preferably be 




Patent ductus arteriosus (small/mild)
Mitral valve prolapse (small/mild)
Successfully repaired simple shunt defects (ASD, VSD, 
PDA, APVR)
Unrepaired ASD or VSD
Repaired tetralogy of Fallot
Turner syndrome without aortic dilatation
Follow- up during pregnancy: once or twice in 
local hospital
Delivery: local hospital




Mild left ventricular impairment (EF>54%)
Native or tissue valve disease not considered WHO I or IV
Marfan or other HTAD syndrome without aortic 
dilatation
Aorta <45mm in bicuspid aortic valve
Repaired coarctation
AVSD
Left ventricular impairment (30-45%)
Mechanical valve
Systemic right ventricle with good or mildly 
impaired function
Fontan (if otherwise well)
Unrepaired cyanotic disease
Moderate mitral stenosis
Severe asymptomatic aortic stenosis
Moderate aortic dilatation
Follow- up during pregnancy: Bimonthly  in 
expert centre
Delivery: Expert centre





WHO IV: pregnancy not recommended
Pulmonary arterial hypertension
Severe systemic ventricular dysfunction (EF<30%)
Moderate systemic right ventricular dysfunction 
Severe mitral stenosis




Fontan with any complication
Follow- up during pregnancy: Monthly 
in expert centre
Delivery: Expert centre
APVR = anomalous pulmonary venous return, ASD = 
atrial septal defect, AVSD = atrioventricular septal 
defect, EF = ejection fraction, ESC = European Society of 
Cardiology, HTAD = hereditary thoracic aorta disease, 
PDA = persistent ductus arteriosus, VSD = ventricular 
septal defect, WHO = World health organization
Adapted and modified for congenital heart disease , 
from the ESC 2018 “Cardiovascular diseases during 
Pregnancy (management of) Guidelines” Table 3
figure 2 Advised counselling.
evaluated using CMR without gadolinium, as the 
effect of gadolinium on the fetus is unknown.12 
CMR in pregnant women is preferred over CT 
because of radiation exposure to the fetus.
Modified WHo risk stratification
The mWHO classification provides a first 
impression about the potential risk of pregnancy 
(figures 1 and 2). A comprehensive description of 
the classification has been published in the latest 
European Society of Cardiology (ESC) guideline 
of pregnancy.3 Class I consists of mild congen-
ital heart disease such as a small patent ductus 
arteriosus or mitral valve prolapse, and repaired 
simple lesions. These lesions are not associated 
with a significant risk of morbidity or mortality 
compared with the general pregnant population. 
The risk of pregnancy gradually increases with an 
extremely high risk in mWHO class IV, including 
women with pulmonary arterial dilatation, severe 
systemic ventricular dysfunction or severe aortic 
dilatation. Women in class I can be cared for in 
a peripheral hospital, while those in class IV are 
advised against pregnancy. The classes mWHO II, 
II–III and III include women at a mild- to- moderate 
increased risk, and evaluation and management 
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Table 1 Lesion- specific risks
Maternal cardiovascular risk
obstetric risk (other than caesarean 
section) fetal/neonatal risk* references
ASD, repaired 3.6% arrhythmia, 3.6% persistent NYHA 
deterioration
11% hypertension/pre- eclampsia, 16% 
PPH
1.8% offspring mortality† Yap BJOG 2009
ASD, unrepaired 4.5% arrhythmia, 3% persistent NYHA 
deterioration, 0.8% TIA
11% hypertension/pre- eclampsia, 8.3% 
PPH
3.0% offspring mortality Yap BJOG 2009
VSD, repaired 2.3% arrhythmia 7% hypertension/pre- eclampsia, 12% 
PPH
21% SGA Yap BJOG 2010
VSD, unrepaired 1% arrhythmia, 1% endocarditis 15% hypertension/pre- eclampsia, 9.6% 
PPH
6.7% SGA, 1% offspring mortality Yap BJOG 2010
PDA ‡ ‡ ‡   
AVSD 23% persistent NYHA deterioration, 19% 
arrhythmias
17% hypertension/pre- eclampsia, 6.3% 
gestational diabetes, 21% PPH
10% SGA, 6.3% neonatal mortality Drenthen EHJ 2005
TOF 8%–12% arrhythmia or heart failure, 2% 
persistent NYHA deterioration
8% hypertension/pre- eclampsia, 10% 
PPH
17%–21% SGA, 18% prematurity, 
6.5% offspring mortality
Meijer Heart 2005, Balci AHJ 
2011, Kampman Us Obst Gyn 
2017
Ebstein 7.3% arrhythmia or heart failure 8.5% PPH 19%–27% prematurity, 18% offspring 
mortality
Connoly JACC 1994, Katsuragi 
AJObstGyn 2013, Lima Arch 
Cardiovasc Dis 2016
LVOT obstruction 3.8%–12% heart failure, 2%–
5.7% arrhythmia, 1% endocarditis
6.4%–11% hypertension/pre- eclampsia, 
4.2% PPH
8%–21% prematurity, 13% SGA, 
0%–1.1% fetal mortality
Silversides AJC 2003, Yap IJC 
2008, Tzemos AHJ 2009, Orwat 
JACC 2016
RVOT obstruction 9% heart failure 15% hypertension- related complication 17% prematurity, 4.8% offspring 
mortality
Drenthen Heart 2006, Greutmann 
EHJ 2010
TGA—after arterial switch 0%–12% arrhythmia or heart failure ‡ 9%–21% prematurity Stoll JAMA card 2018, Tobler Am 
J Car 2010, Fricke Heart Lung Circ 
2019, Horiuchi J Card 2019
TGA—after atrial repair 6.6%–22% arrhythmia, 11%–14% persistent 
NYHA deterioration
18% hypertension/pre- eclampsia, 14% 
PPH
24%–38% prematurity, 22%–38% 
SGA, 12% offspring mortality
Drenthen EHJ 2005, Cataldo BJOG 
2016, Trigas Circ J 2014
ccTGA 26%–32% heart failure, CVA or worsening 
of cyanosis
2% hypertension/pre- eclampsia, 14% 
PPH
9% prematurity, 1.3% offspring 
mortality
Therrien Am J Card 1999, Gelson 
EJOG 2011, Drenthen JACC 2007
Fontan 3%–37% arrhythmia, 4% thrombotic event, 
3%–11% heart failure
14% PPH 59% prematurity, 20% SGA, 7.6%–
17% offspring mortality
Garcia Ropero Circ CV Qual 
Outcomes 2018
Cyanotic disease 32% heart failure, arrhythmia or progression 
of hypoxaemia
10% PPH 37% prematurity, up to 24% fetal 
mortality
Ladouceur Circ 2017, Presbitero 
Circ 1994, Drenthen JACC 2007
PAH in CHD
(note: very broad spectrum 
of results)
0%–28% mortality, 31%–35% RV failure, 
7% pulmonary hypertensive crisis, 7%–
14% thromboembolism, 9% arrhythmia
0%–6% pre- eclampsia, 0%–38% PPH 17%–86% prematurity, 0%–
7% offspring mortality
Thomas JAHA 2017, Sliwa EJHF 
2016, Bedard EHJ 2009
Eisenmenger 36% mortality, 21%–45% heart failure, 19% 
thromboembolism
29% PPH 65%–88%% prematurity, 38%–83% 
SGA, 10%–27% fetal mortality, 
18%–25% perinatal mortality
Drenthen JACC 2007, Duan BMC 
Pregnancy and Childbith 2016
Coarctation None reported 22% hypertension/pre- eclampsia 2% offspring mortality Vriend EHJ 2005
This is a generalisation of lesions with very heterogenous patients, included in both prospective and retrospective studies. Specific characteristics such as ventricular dysfunction, valve stenosis or 
regurgitation, cyanosis and the presence of a mechanical valve may impact risks to a large extent. For detailed information, we recommend to evaluate the papers referred to in the last column. 
The full references are available in the online additional material (online supplementary file 2).
*SGA and prematurity only reported if >10%.
†Offspring mortality: late fetal death or neonatal death.
‡Not reported.
ASD, atrial septal defect; AVSD, atrioventricular septal defect; ccTGA, congenitally corrected transposition of the great arteries; CHD, congenital heart disease; CVA, cerebrovascular accident; LVOT, 
left ventricular outflow tract; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PDA, persistent ductus arteriosus; PPH, postpartum haemorrhage; RVOT, right ventricular 
outflow tract; SGA, small for gestational age; TGA, transposition of the great arteries; TIA, transient ischaemic attack; TOF, tetralogy of Fallot; VSD, ventricular septal defect.
during pregnancy is required accordingly in a 
tertiary centre. The mWHO classification is based 
on expert opinion. It has been tested in several 
cohorts, and has a moderate discriminative capa-
bility in women with congenital heart disease. 
Therefore, the classification provides mainly a 
first impression, and more detailed information 
about pregnancy risks should be obtained through 
additional clinical information, as included in the 
risk tools mentioned in the paragraph directly 
hereafter.
Clinical risk scores: CarPrEG II and ZaHara
The CARPREG was the first risk tool for preg-
nancy and heart disease, developed in 2001.13 
Recently, it was updated and the CARPREG 
II risk score performed clearly better.14 The 
risk predictors are shown in figure 1 and were 
derived from, and validated in, a large Canadian 
cohort of women with heart disease in general, 
of whom 64% had congenital heart disease. The 
authors also show the additive information of the 
CARPREG II predictors on top of the mWHO 
classification.
The ZAHARA risk score was developed in partic-
ular for women with congenital heart disease.15 
Predictors are listed in figure 1. Two predictors of 
this risk prediction rule are not mentioned in the 
CARPREG II study: the use of cardiac medication, 
and atrioventricular regurgitation.
The Registry Of Pregnancy And Cardiac 
disease (ROPAC) showed improved accuracy of 
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the WHO classification, by adding prepregnancy 
atrial fibrillation and signs of heart failure to the 
classification.10
Validation of all tools in different congenital 
heart disease cohorts lead to different results.9 16–18 
This is probably driven by several factors. First, 
not all cohorts focused on congenital heart 
disease only and congenital heart disease consists 
of a very broad spectrum of cardiac lesions. Also, 
centre- specific care and logistic issues such as local 
infrastructure may influence outcome. Finally, 
patient- specific factors such as late presentation 
or patient adherence may hamper the discrim-
inative accuracy. The above- mentioned scoring 
systems should not be seen as standalone tools: 
individualised care is crucial based on both type 
of lesion and clinical features, and evaluated in a 
multidisciplinary team as discussed hereafter.
HIGH rIsk CHaraCTErIsTICs and 
ConGEnITaL dEfECTs
Table 1 presents lesion- specific risks for several 
frequently encountered congenital heart defects. 
Lesions with high- risk characteristics are discussed 
in detail in this paragraph. In this section, several 
specific recommendations are discussed. In 
general, the ESC guidelines for the management 
of cardiovascular diseases during pregnancy is a 
dedicated guideline that can be helpful to all care 
providers dealing with women with congenital 
heart disease in childbearing age.
In general, women with characteristics discussed 
ahead are in modified WHO class III or IV. Women 
in class IV should be advised against pregnancy 
following the latest guidelines. However, some 
women decide to pursue on embarking preg-
nancy and do return pregnant to the outpatient 
clinic. Therefore, we will discuss the main issues, 
and how to perform follow- up in these high- 
risk situations. Without exception, these women 
need referral and frequent follow- up in a tertiary 
centre.
Pulmonary arterial hypertension
Pulmonary arterial hypertension is indicated 
as modified WHO class IV. It is associated with 
a substantial risk of heart failure, ventricular 
arrhythmias for the mother and also an increased 
mortality risk, although outcome seems to be 
better in the current era of advanced therapies. 
Poor outcome for the fetus is another reason to be 
very restrained with positive advice on pregnancy. 
It must be marked that evidence on outcome is 
limited. Maternal mortality varies from abso-
lute high risk of 28%, to slight improvement in 
outcome in selected patients with congenital 
heart disease, but still a maternal mortality rate of 
7%.19 20 Counselling about the high- risk and thus 
absolute contraindication to pregnancy remains 
paramount. When women do become pregnant, 
options on termination should be given. Other-
wise, a plan on strict follow- up, advanced therapy 
and delivery should be made in a multidisciplinary 
team with expertise in pulmonary hypertension.
In case of Eisenmenger syndrome, there is 
also an absolute contraindication for pregnancy. 
Pregnancy- induced decrease in peripheral vascular 
resistance causes an additional risk of progres-
sive right- to- left shunt, cyanosis and paradoxical 
emboli. Very poor fetal outcome can be expected 
in the majority of cases.20
Cyanosis
Cyanotic disease at adult age may exist in the pres-
ence of persistent or uncorrected shunt defects. 
Early studies showed high numbers of complicated 
pregnancies in women with cyanotic heart disease. 
Recently, a retrospective study included 71 preg-
nancies in 31 women with cyanotic heart disease, 
without pulmonary arterial hypertension.21 Only 
two women had systemic ventricle dysfunction. 
Up to 32% of patients developed cardiovascular 
complications during pregnancy, mainly heart 
failure and progression of hypoxaemia requiring 
hospitalisation. Also, late follow- up (with a broad 
range of 1–15 years) revealed another 13% of 
chronic heart failure, although natural course 
may also prompt these late complications. In 
general, the underlying cardiac lesion will mainly 
influence maternal risk. The severity of cyanosis 
confines the chance of a completed pregnancy 
ending in live birth, with a disappointing low 
number of live births of only 12% in patients with 
a saturation below 85%.22 Women with a satura-
tion level below 85% are therefore discouraged 
on embarking pregnancy.
fontan
In women with a Fontan circulation, other reasons 
than cyanosis also influence the level of risk asso-
ciated with pregnancy. Mainly systemic ventricular 
dysfunction, and significant atrioventricular valve 
regurgitation and protein- losing enteropathy are 
clinical factors associated with higher complication 
rates. Major complications are heart failure, supra-
ventricular arrhythmias, thromboembolic events 
and bleeding. Next to these frequent maternal 
complications, the chance of a pregnancy loss is 
around 70%.23
systemic ventricular dysfunction
Any type of congenital heart disease with a dimin-
ished ventricular dysfunction is at risk of deterio-
ration during pregnancy. It is an independent risk 
factor for a complicated pregnancy, as listed by the 
CARPREG, ZAHARA and ROPAC studies. Signs 
of heart failure before pregnancy should be treated 
first as it is a clear additional risk factor. Women 
with severely diminished left ventricle function, or 
a moderate systemic right ventricle function should 
be advised against pregnancy.3
aortic dilatation
Women with aortic disease may face the risk of 
further dilatation, or worse, dissection during 
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Table 2 Recurrence risk of congenital heart disease
Atrial septal defect 4.5%–6%
Ventricular septal defect 6%–9.5%
Patent ductus arteriosus 4%
Atrioventricular septal defect 7.5%–15%
Ebstein 3.9%–6%
Tetralogy of Fallot 2.5%–10%*
Transposition of the great arteries 0.5%†
Bicuspid aortic valve 4.6%–9.3%
Aortic coarctation 4%
Marfan syndrome 50%
Pulmonary valve stenosis 7%
Modified and updated from van Hagen/Roos- Hesselink, SA Heart 2014.
*Range varies to 50% if associated with 22q11.2 deletion.
†Total recurrence risk, affected mother or father.
pregnancy. The extent of diameter growth during 
pregnancy is difficult to predict and the results 
diverge between no significant growth up to 3 mm 
growth during the entire pregnancy with potential 
decrease of diameter after pregnancy.24–26 The risk 
of dissection depends on the underlying syndrome, 
as it does outside pregnancy. Hence, women with 
Marfan syndrome and Loeys- Dietz syndrome are 
at highest risk. In the absence of Marfan syndrome 
or other high- risk heritable thoracic aortic disease 
(HTAD), a cut- off of 50 mm, also in the pres-
ence of a bicuspid valve is used to advise against 
pregnancy. In Marfan syndrome and Loeys- Dietz 
syndrome or other HTAD, women should not 
embark on pregnancy in the presence of an aortic 
root diameter >45 mm.3 In Turner syndrome, 
diameters specifically need to be corrected for 
body surface area, and a threshold of 27 mm/m2 
is adopted.27 Elective surgery in women beyond 
these thresholds may be considered, however the 
risk of type B dissection and other complications 
is still not zero after surgery. Risk factors such as 
(family) history of dissection also need to be taken 
into account.
A caesarean section is advised in all women with 
an aortic root diameter >45 mm. Below 40 mm, 
a vaginal delivery is considered safe. Between 40 
and 45 mm the choice may depend on diameter 
growth during pregnancy and risk factors for 
dissection.
Mechanical valve
The presence of a mechanical valve is an inde-
pendent risk factor of complications. The balance 
between thrombotic and bleeding risks determine 
the chance of a successful uncomplicated preg-
nancy, which was about 57% in a large registry 
of women with a mechanical valve prosthesis.28 
A valve thrombosis occurred in 4.7%, and 20% 
of these women died. Anticoagulation strategies 
are predefined in the ESC guidelines, but a broad 
spectrum of regimes used globally, emphasises 
the difficulty of anticoagulation management. In 
women who are not on low- dose vitamin K antag-
onists, a switch to some type of heparin in the first 
trimester is advised, due to the teratogenicity of 
vitamin K antagonists. To limit the risk of throm-
bosis with heparin, women should be switched 
back to a vitamin K antagonist at the start of the 
second trimester, until the 36th week. A plan for 
heparin prescription around delivery should be 
ready. However, still there is no clear consensus 
on the best anticoagulation regime.3 29 30
CounsELLInG
Prepregnancy counselling is crucial to identify the 
high- risk patients, and to reassure many patients 
who are at low risk, because pregnancy is well 
tolerated in most women with congenital heart 
disease. During counselling several topics need 
to be discussed: the risk for the mother and for 
the fetus, medication use and possible adaptations 
needed before pregnancy, the recurrence risk for 
congenital heart disease in the baby and the long- 
term outcome for the mother. Also reproductive 
therapies and contraception need attention.
Maternal and fetal risk
In the largest prospective cohort of 3295 preg-
nant women with congenital heart disease, 
mortality occurred in 0.2%, heart failure in 6.2%, 
an arrhythmia in 2%, a thrombotic event in 1% 
and aortic dissection in 0.03%.31 As discussed, 
the maternal and fetal risks depend on the under-
lying disease. In general, the risk of heart failure, 
arrhythmias and deterioration of cardiac defect 
should be mentioned during counselling. figure 1 
can guide in the emphasis to be made in each indi-
vidual based on their clinical characteristics. In 
women with aorta pathology, after risk stratifica-
tion, the risk of aortic dissection needs discussion.
Obstetric events such as pregnancy- induced 
hypertension (3%), (pre- )eclampsia (2%) and 
postpartum haemorrhage (3%) do not occur more 
often in women with congenital heart disease 
in general.31 Caesarean section is performed in 
as much as 40% of women, while it is generally 
preserved for women with an obstetric indi-
cation or in a high- risk situation such as heart 
failure, early labour while on oral anticoagula-
tion or in advanced pulmonary hypertension or 
Eisenmenger.
Overall, uteroplacental flow is lower in women 
with congenital heart disease, compared with 
normal pregnant women. An impaired uteropla-
cental flow is associated with adverse fetal and 
neonatal outcome.32 As such, fetal growth restric-
tion occurs more often in mothers with a complex 
congenital heart disease.33 Women with congenital 
heart disease face a higher risk of fetal mortality 
(1%), premature birth (14%) and a low Apgar 
score (6%).31 Neonatal death occurs in 0.5% and 
is comparable to the background population, but 
this depends on the underlying congenital diag-
nosis of the mother (table 1).
assisted reproductive therapies
With the advancing technologies conception also 
becomes an option for women with congenital 
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heart disease dealing with subfertility or infer-
tility. However, assisted reproductive therapies 
may be prothrombotic and may induce hyper-
tensive complications, depending on the method 
and doses used. Overstimulation can lead to 
ovarian hyperstimulation syndrome. There is an 
additional risk of conceiving multiple pregnancy 
which may be poorly tolerated. Thus, women in 
high- risk conditions such as WHO class III and 
IV should be discouraged to use these advanced 
methods if it requires hormonal stimulation, or at 
least natural cycle options should be considered to 
prevent the risk of overstimulation.3
Contraception
Women with congenital heart disease are sexually 
active at about the same age as other women, with a 
significant amount of unintended pregnancies.34 35 
Women with a high- risk condition, or those who 
are advised against pregnancy, need careful advice 
about contractive methods already at young age. 
A balanced choice needs to be made between 
effectiveness, safety and personal preference. 
Little data are available on safety of contraception 
in women with congenital heart disease.36 Oral 
contraception may be associated with a potential 
increased risk of thromboembolic complications, 
specifically in women with an increased risk of 
thrombosis, such as a Fontan palliation, although 
the evidence is contradictory. Thrombosis risk is 
highest in ethinyloestradiol- containing contracep-
tives. Progestin- only contraceptives are a suitable 
alternative. Levonorgestrel- based intrauterine 
devices are probably safest.37 Irreversible options 
such as tubal occlusion or vasectomy are a serious 
option to discuss with women in WHO class IV, 
although there is a general increased operation 
risk including postoperative infection.
Case reports are available on endocarditis 
following intrauterine device implantation in 
specific congenital heart diseases such as Fallot.38 
Since there is no evidence that the risk of endocar-
ditis is increased compared with the background 
population, endocarditis prophylaxis is not indi-
cated in genitourinary tract procedures.39
recurrence risk
Part of the preconception counselling is the risk of 
recurrence of congenital heart disease in offspring 
as it is increased. The extent of recurrence risk 
depends on underlying defect. In autosomal 
dominant diseases such as Marfan syndrome, the 
risk is obviously 50%. In the absence of a clear 
genetic diagnosis, the risk is estimated at 2.9% 
for all offspring of women with congenital heart 
disease.40 The specified recurrence risks are listed 
in table 2. In all patients with congenital heart 
disease, genetic counselling may be considered. 
Particularly in those with aortic disease, those 
who have other affected family members or if 
other non- cardiac congenital abnormalities might 
be present. In patients with a known genetic 
defect, preimplantation diagnostic testing has 
become available.41
Medication
Medication used before pregnancy should be 
evaluated for teratogenicity. ACE inhibitors and 
angiotensin receptor blockers (ARB) have poten-
tial adverse effects on the fetus and are therefore 
contraindicated. In women who are prescribed 
ACE inhibitors or ARB, a prepregnancy trial 
without these agents may show whether they 
remain stable. In women with high risk of heart 
failure, already pregnant, the risk of discontinuing 
may outweigh potential fetal risks, a balance to 
be made by the physician. Beta- blockers can be 
continued, with strict fetal monitoring because 
of potential low birth weight. Atenolol is contra-
indicated during pregnancy, because of reported 
birth defects. Life- threatening acute heart failure 
during pregnancy should be treated as outside 
pregnancy, with no restrictions, to enable the 
mother to survive such a hazardous event. The 
FDA classification has been replaced by the Preg-
nancy and Lactation Labelling Rule, and can be 
found in prescription labels, and online on the 
website of both the FDA42 and the EMA.43 Evalu-
ation of this information is key to enable counsel-
ling and provide the best available information on 
medication during pregnancy.
foLLoW-uP durInG PrEGnanCy
Frequency of clinical follow- up depends on risk strat-
ification. Women with a low- risk diagnosis can be 
seen once or twice in a local hospital. In WHO class 
II, it is advised to evaluate at least every trimester. If 
unremarkable than both follow- up and delivery can 
take place in a local hospital. Women in WHO II- III 
and higher require follow- up in a dedicated expert 
centre, and at least bimonthly, increasing per WHO 
class. Women with cyanosis, pulmonary hyperten-
sion or systemic ventricular dysfunction require 
weekly or biweekly follow- up in the third trimester. 
Advise on follow- up is summarised in figure 2. A 
delivery plan should be made in a multidisciplinary 
team consisting of at least a cardiologist, obstetri-
cian and anaesthesiologist.3
The default mode of delivery in almost all 
women with congenital heart disease is vaginal with 
spontaneous labour. Exceptions are to be made 
for obstetric reasons, or in case of a very high- risk 
cardiac situation as mentioned before. In general, 
no benefit has been found for caesarean section 
over vaginal delivery, while gestational age and 
birth weight in women with a caesarean section is 
lower.44 All women with congenital heart disease 
should deliver in a hospital and in moderate- to- 
complex disease in an expert centre.
Additional haemodynamic monitoring during 
delivery might be required in women who are at risk 
of acute heart failure or arrhythmias. The first step is 
pulse oximetry, which includes continuous heart rate 
monitoring. In advanced risk patients, continuous 
ECG monitoring should be considered. An arterial 
8 van Hagen IM, Roos- Hesselink JW. Heart 2020;0:1–9. doi:10.1136/heartjnl-2019-314702
Education in Heart
key messages
 ► Prepregnancy prediction of risks for both mother and child can be done 
based on lesion- specific tools and clinical characteristics.
 ► The available risk tools all have their limitations, and interpretation needs to 
be done with care.
 ► The modified WHO classification is the first step in guiding management and 
follow- up during pregnancy.
 ► Clinical characteristics, as provided by the WHO, CARdiac disease in 
PREGnancy, Zwangerschap bij Aangeboren HARtAfwijking and Registry Of 
Pregnancy And Cardiac disease studies, and as listed in figure 1, may further 
define individual risk.
 ► Counselling should at least consist of explanation of maternal and fetal risks, 
recurrence risk, evaluation of medication, options for contraception and risks 
of assisted reproductive therapy.
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catheter for invasive blood pressure monitoring or 
non- invasive cardiac output measurement provides 
close follow- up in women who are in WHO class 
IV, or clinically instable. In suspected high risk of 
heart failure, consider prolonged observation up to 
48 hours after delivery, since this is the timespan of 
large fluid shifts inducing clinical deterioration.45
suMMary
Risk prediction and counselling are the key to limit 
risks of complications during pregnancy in women 
with congenital heart disease. The WHO classifica-
tion and clinical risk tools will guide the physician 
to the best available risk estimate, but an individu-
alised approach and expert opinion remains para-
mount in counselling women with congenital heart 
disease with a pregnancy wish. In women with an 
estimated low- risk or intermediate- risk pregnancy, 
planned follow- up and a delivery plan made by a 
multidisciplinary team provides the best chance of 
an uncomplicated pregnancy. While the majority do 
well, there is a small group of women that need an 
explicit advice not to embark pregnancy, to prevent 
devastating situations.
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